S. Phan

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +15

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak et al. · Journal of Clinical Oncology · 2003 · 587 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2013 · 477 citations · Full text

Medicine, Oncology, Pharmacology +17

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases

Minesh P. Mehta, Patrick Rodrigus, C. Terhaard et al. · Journal of Clinical Oncology · 2003 · 464 citations

Medicine, Oncology, Radiation Oncology +17

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine–DNA Methyltransferase Biomarker Analyses

Timothy F. Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta et al. · Journal of Clinical Oncology · 2017 · 144 citations

Medicine, Oncology, Pharmacology +15